<<It's probably similar to buying a couple dozen lottery tickets for an avg. person.>>
While I have no inside information as to Jim Coleman's financial wherewithal, there is nothing in his employment history (Pharmacia--CoCensys--consulting--Cortex) that would point to the accumulation of great wealth. And my direct experience of him would point to the contrary--he's worked for whatever he has. So the notion that a 20K outlay for him is like "a couple dozen lottery tickets" for most people is--IMHO--totally incorrect. That to me is a significant chunk o' change, and it is for him as well.
Gfp is correct in noting that nothing imminent is lined up deal-wise, which allows Coleman to make this purchase. But it obviously does indicate confidence that the pps per share will improve. But I personally didnt need to see this purchase to believe that. Pierre Tran's signing on to me is a much more compelling indicator of belief in the company's prospects.
Re: Lynch and Simmon. Neither is an insider, purchases would not be publicly disclosed unless they broke the barrier for SEC disclosure, not likely. Vince Simmon continues to own his stock, so far as I know.
NeuroInvestment
Market Data 
Markets 
AI
